Business of CDMO services expands to Korea market.
TuNEX(ENIA11) gets approval for the first new biological entity market authorization from TFDA.
Mycenax Biotech Inc.
Please select the category
2018
Business of CDMO services expands to Korea market.
TuNEX(ENIA11) gets approval for the first new biological entity market authorization from TFDA.
2017
Fill/Finishing line was upgraded, and increased a new container cartridge aseptic line. Business of CDMO services expands to China market.
Business of CDMO services expands to the US market.
2016
Mycenax in-house MBICHO medium has been innovated for improving the competitive capacity of CDMO services.
The third manufacturing line started to construct.
2015
Mycenax signed an agreement of contract manufacturing biologics with an Australian biopharma. Business of CDMO services expands to Australia market.
2014
Development project of LusiNEX received grants from MEA.
Mycenax signed an agreement of contract manufacturing biologics with Japanese biopharma. CDMO services expand to Japan market.
Completed construction of 2000L bioreactor as the first in Taiwan.。
2013
Mycenax Cooperate stock was officially listed on Stock Exchange at Dec. 25, 2013.
Mycenax began the development project of LusiNEX.
Mycenax received PIC/S GMP certificate from TFDA.
TuNEX received a silver award of Pharmaceutical Technology Research and Development Award from TFDA.
Mycenax signed an agreement of contract manufacturing biologics with European biopharma. CDMO services expanded to the EU market.
2012
Mycenax partnered with TSH Biopharm, for TSH to be responsible for phase III clinical trial and NDA submission, and Myce
2011
TFDA approved phase III clinical trial of TuNEX in Taiwan.
2009
TuNEX received approval to enter phase III clinical trial from Korea FDA.
2008
Mycenax received a bronze award of Taiwan Biotech industry Awards.
Mycenax was registered as the listed company at the emerging stock market. Mycenax was categorized formally as biopharmaceutical company by MEA.
Started to conduct the second tier of MEA Industrial TDP, from Aug. 2008 -
2007
TuNEX was approved to enter phase I/II clinical trial.
The development project of GranNEX started to conduct and was supported by MEA Industrial TDP.
2006
Issued the IPO (4726).
2005
Mycenax conducted Follow-on Biologics project granted by MEA for TuNEX pre-clinical development from Aug. 2005 to Jul. 2
Registered DMF to FDA (DMF no.17981)
2003
Completed construction of biologics plant in Jhunan Science Park.
2002
Established and installed in Jhunan Science Park.
2001
Myceanx was established in Xindian Dist., New Taipei City.